Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23091IDB-L5

Select Item

Empower your strategies with our Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2024 report and make more profitable business decisions.

Chronic myeloid leukemia (CML), also known as chronic myelocytic leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age, and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen, and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation, and chemotherapy.

The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) drugs in development market research report provide comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Key Targets
· Bcr-Abl Tyrosine Kinase; B Lymphocyte Antigen CD19; B Cell Receptor CD22; Interleukin 3 Receptor Subunit Alpha; Tyrosine Protein Kinase ABL1; DNA (Cytosine 5) Methyltransferase 1; CD3 ; Myeloid Cell Surface Antigen CD33; Receptor Type Tyrosine Protein Kinase FLT3; and Mast/Stem Cell Growth Factor Receptor Kit
Key Mechanisms of Action
· Bcr-Abl Tyrosine Kinase Inhibitor; Interleukin 3 Receptor Subunit Alpha Antagonist; Tyrosine Protein Kinase ABL1 Inhibitor; Signal Transducer And Activator Of Transcription 5 Inhibitor; Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor; DNA (Cytosine 5) Methyltransferase 1 Inhibitor; CD3 Agonist; Catenin Beta 1 Inhibitor; Cell Division Cycle 7 Related Protein Kinase Inhibitor; and Cytotoxic T Lymphocyte Protein 4 Antagonist
Key Routes of Administration
· Oral; Intravenous; Parenteral; Subcutaneous; Intrathecal; Intravenous Drip; Intramuscular; Intraperitoneal; and Intralesional
Key Molecule Types
· Small Molecule; Cell Therapy; Gene-Modified Cell Therapy; Monoclonal Antibody; Monoclonal Antibody Conjugated; Fusion Protein; Antisense Oligonucleotide; Recombinant Protein; Subunit Vaccine; and Recombinant Vector Vaccine
Major Companies
· Bristol-Myers Squibb Co; Henan Provincial People's Hospital; Pfizer Inc; Orca Biosystems Inc; Xspray Pharma AB; Handa Pharmaceuticals LLC; Lotus Pharmaceutical Co Ltd; Millennium Pharmaceuticals Inc; Novelty Nobility Inc; and Brillian Pharma Inc.

Scope

  • Therapeutics in Development: Covering 105 molecules, with 84 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
Actinium Pharmaceuticals Inc
Al-Azhar University
AOP Health
Arromax Pharmatech Co Ltd
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
Autolus Therapeutics Plc
Bio-Path Holdings Inc
Brillian Pharma Inc.
Bristol-Myers Squibb Co
Celularity Inc
Central Drug Research Institute
Charite University Hospital of Berlin
Chimeric Therapeutics Ltd
Coeptis Therapeutics Holdings Inc
Curis Inc
Enliven Therapeutics Inc
Escend Pharmaceuticals Inc
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fusion Pharmaceuticals US Inc
Gamida Cell Ltd
Gifu University
GT Biopharma Inc
Handa Pharmaceuticals LLC
HEC Pharma Co Ltd
Helocyte Biosciences Inc
Henan Provincial People's Hospital
HighPass Bio Inc
Housey Pharmaceutical Research Laboratories LLC
iCell Gene Therapeutics LLC
Ilyang Pharmaceutical Co Ltd
ImmunoForge Co Ltd
IN8bio Inc
Inhibikase Therapeutics Inc
InnoCure Therapeutics Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Kartos Therapeutics Inc
Kiadis Pharma NV
Kura Oncology Inc
Lin Bioscience Inc
Lotus Pharmaceutical Co Ltd
MAA Laboratories Inc
MacroGenics Inc
Mana Therapeutics Inc
MedPacto Inc
Medytox Inc
Millennium Pharmaceuticals Inc
Nanjing Sanhome Pharmaceutical Co Ltd
Nanocopoeia LLC
Novartis AG
Novelty Nobility Inc
Oncologia no Hospital de Clinicas de Porto Alegre
Orca Biosystems Inc
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
PharmaEssentia Corp
Prescient Therapeutics Ltd
PRISM Pharma Co.
Ltd.
PYC Therapeutics Ltd
Radboud University
Samsung Medical Center
Sanofi
ShanghaiTech University
Shenogen Pharma Group Ltd
Shenzhen Targetrx Inc
Shorla Oncology
Stanford University
Sun Pharma Advanced Research Company Ltd
Synactix Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Terns Pharmaceuticals Inc
The First Affiliated Hospital of the University of Science and Technology of China
Theseus Pharmaceuticals Inc
Tohoku University
TotalClarity Inc
University Medical Center Utrecht
University of California San Diego
University of Chicago
University of Haifa
University of Palermo
University of Science and Technology of China
University of Texas MD Anderson Cancer Center
Vincerx Pharma Inc
Xencor Inc
Xspray Pharma AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) reports
Pharmaceuticals
New
Human Immunodeficiency Virus (HIV) Major Markets: Disease Management, Epidemiology, Pipeline…
$17,995 | March 2026
Pharmaceuticals
New
Catalyst Monitor: Q2 2026 Outlook
$1,870 | March 2026
Pharmaceuticals
New
Emerging Market Outsourcing Report, Q1 2026
$2,950 | March 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2024 in real time.

  • Access a live Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more